Each summer, Clarivate publish their annual Journal Citation Report, assigning Impact Factors to eligible academic journals which meet Clarivate’s criteria for ranking. We’re pleased to announce that both Clinical & Experimental Immunology (CEI) and Immunotherapy Advances (ITA) have seen an increase in Impact Factor this year.
We are pleased to announce that the impact factor of our open access journal Immunotherapy Advances has increased to 4.9, reinforcing the journal as a leading publication for immunotherapy research. Meanwhile, journal Clinical & Experimental Immunology achieved an impact factor of 3.8 and has risen to the second quartile for immunology journals. These new metrics place Immunotherapy Advances in the first quartile for immunology journals.
This is a great achievement for both Immunotherapy Advances and Clinical & Experimental Immunology , and we’d like to thank the editorial team for their incredible hard work, led by founding Editor-in-Chief of ITA, Professor Tim Elliott and Editor-in-Chief of CEI, Professor Claudia Mauri. We are also deeply grateful to everyone who has contributed to the journal’s continued success, including our authors, readers, reviewers, and editors.
Our youngest journal, Discovery Immunology, does not yet have an impact factor, but is indexed in PubMed Central, one of the largest and most widely used repositories for biomedical and life sciences articles. Discovery Immunology also expanded its scope in 2024 to include veterinary immunology.
Impact factors are one of a range of measures that indicate the performance of a journal, and it is important to see them in their wider context. Below we set out some of the other key metrics and milestones for our three journals. Together, these demonstrate that we are continuing to achieve our goal of publishing high quality content that is timely and relevant to our research community.
Whilst we are aware that the impact factor has certain limitations, we take this as one measure of the high-quality work submitted by our authors.
We would also like to take this opportunity to highlight other key metrics and milestones, which demonstrate that we are continuing to achieve our goal of publishing content that is timely and relevant to our research community.
Clinical & Experimental Immunology
- Mean time to first decision: 21 days
- Mean time to final decision: 36 days
- 82,616 Altmetric mentions in the last year
- Yearly usage: 622,576 full-text downloads
- CiteScore 2024: 7.5
- Mean time to first decision: 33 days
- Mean time to final decision: 72 days
- 7,890 Altmetric mentions in the last year
- Yearly usage: 61,176 full-text downloads
- CiteScore 2024: 8.3
- Indexed in the PubMed Central, Scopus and the Directory of Open Access Journals
- Mean time to first decision: 36 days
- Mean time to final decision: 85 days
- 5,773 Altmetric mentions in the last year
- Yearly usage: 44,566 full-text downloads
- CiteScore 2024: 2.0
- Indexed in the Directory of Open Access Journals, Dimensions and Google Scholar
Explore our most read content:
Clinical & Experimental Immunology:
This article explores how emerging T-cell–based therapies, such as CAR T-cell therapy and T-cell engagers, could overcome resistance to traditional B-cell depletion in autoimmune diseases. By disrupting B–T-cell collaboration, especially in hard-to-reach tissues, these approaches offer promising alternatives for patients with refractory conditions like lupus, rheumatoid arthritis, and multiple sclerosis.
Quantifying microglial morphology: an insight into function
This article highlights the critical role of microglial morphology as an indicator of inflammation and tissue damage in the central nervous system. While microglial shape alone doesn’t define function, it offers valuable insights when paired with genetic and histological analyses. The article emphasizes that combining high-quality immunohistochemistry with molecular approaches is key to understanding microglial behaviour in health and disease.
Phase 3 vaccine trials are undergoing a major transformation, moving beyond traditional fixed designs toward more flexible and efficient methodologies. This article outlines how modern approaches, such as adaptive trial designs, Bayesian statistics, the estimand framework, and machine learning - are reshaping how vaccines are evaluated for safety and efficacy. These innovations support more ethical and responsive trials, allowing for earlier decisions based on accumulating data. As the demand for rapid, reliable vaccine development grows, these advances are setting a new standard for clinical trial design in the 21st century.
Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review
Bispecific T-cell engagers (BiTEs) connect T cells to tumour cells without relying on MHC or traditional T-cell receptor signalling, making them an innovative tool in cancer immunotherapy. While they have proven effective in blood cancers, their use in solid tumours has faced challenges including toxicity, short half-life, and limited access to tumour sites. This article examines recent strategies to improve BiTE performance, such as Fc-silenced, half-life extended formats, and reviews emerging targets like PSMA, DLL3, and EGFRvIII. BiTEs hold strong potential, particularly when used alongside other immunotherapies, in expanding treatment options for solid tumours.
This study analysed 50 real-world studies to evaluate how well Pfizer/BioNTech and Moderna mRNA vaccines prevent COVID-19 hospitalizations. Both two- and three-dose regimens showed high effectiveness, ranging from 84% to 86%. Booster doses helped restore protection, though effectiveness declined during the Omicron wave. The results support continued vaccine monitoring as new variants emerge.
This study used mathematical models to analyse factors influencing CAR T-cell behaviour in lymphoma patients during the first month after infusion. Both antigen-dependent and independent proliferation significantly affected CAR T-cell dynamics, with antigen-independent growth linked to patient IL-15 and IL-7 levels. Lymphodepletion and tumour burden had more impact than CAR T-cell subtype proportions. The modelling approach offers a valuable tool to predict patient response and guide future CAR T-cell therapies.
Deciphering the relationship between temperature and immunity
This article examines how temperature influences immune responses, highlighting the complex interplay between fever, cellular heat responses, and disease progression. It discusses findings such as extreme mitochondrial heat in T cells and the varying temperature sensitivities of immune cells. Understanding these temperature-immune interactions is increasingly important, especially with rising global temperatures and changing disease patterns, and may help explain factors like sex differences in disease prevalence.
Unravelling monocyte functions: from the guardians of health to the regulators of disease
Monocytes play a vital role in the innate immune system, developing in the bone marrow and giving rise to diverse subsets that maintain tissue health. This article explores how monocytes contribute to normal tissue function and how they adapt during disease to resolve inflammation and restore balance. Understanding their complex development and roles offers important insights into both health and disease processes.
Interleukin-15 (IL-15) plays a dual role in the immune system: at low levels, it supports immune homeostasis, while increased IL-15 during infections or autoimmune conditions promotes inflammation. This article explains how IL-15, through its receptor IL-15Rα, maintains lymphocyte populations like NK and tissue-resident T cells but also triggers inflammatory responses when overexpressed. Understanding these signalling pathways highlights IL-15 as a potential target for immunotherapy in autoimmune diseases.
You can find more information about our journals here: Clinical & Experimental Immunology, Immunotherapy Advances and Discovery Immunology. We offer a broad suite of additional benefits to authors, including a very rapid time to first decision, live Altmetric tracking on your articles, no page or colour charges for members, integration with Publons, and the skills of a dedicated marketing team who will promote your article to interested parties. To support equitable publishing, APC waivers are automatically applied for authors based in eligible low and middle income countries, with additional discretionary waivers available to ensure access for all.
Profits derived from the sale of the journals are invested back into the BSI to benefit our members in the form of grants, travel awards, BSI Regional and Affinity Group meetings, our popular BSI Congress and other key initiatives. We encourage you to support the BSI by submitting your work.
You can share your papers online and keep up to date with news from the journals by following @CEIjournal, @IMTadvances and @discovimmunol on Twitter.